AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data

Max Gelman

Senior Editor

German small-cap Affimed has long been highlighted as a potential Cinderella story, winning milestone-rich deals with Genentech and Roivant. And on Friday the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

AACR: Ger­many's small NK cell play­er Af­fimed makes a big splash with ear­ly lym­phoma da­ta

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data